HELP · Cybin Inc. · Stock research

ём# HELP — Helus Pharma Inc.

Current Thesis

Helus is a clinical-stage CNS developer whose quote is set by flow, not by data. A social-velocity melt-up in late June pushed the RSI into the mid-90s; management met that bid on 2026-06-24 with 10.3M shares at $4.85 (~$50M gross), fixing a company-validated clearing price roughly an order of magnitude below where the sell-side models the asset. Since then the story has quieted rather than broken: HC Wainwright maintained Buy on 2026-07-09 while cutting its target to $70, Canaccord maintained Buy on 2026-07-01 at $42, and on 2026-07-16 HELP printed as a session gainer inside a moving psychedelic/CNS cohort that also included ATAI and CMPS. That cohort move is the one genuinely new input — it argues the theme is re-firing rather than dead — but a second flow impulse into a micro float with no dated catalyst is a trade for a base, not a chase. The underwritable event, the APPROACH Phase 3 of HLP003 in adjunctive major depressive disorder, only began enrolling 2026-06-24 and reads out quarters-to-years out.

Bullish and bearish views on Cybin Inc.

The model's bull view on Cybin Inc. (HELP), in brief: 2026-07-16: HELP appeared in two separate gainer screens alongside ATAI and CMPS. The bear view: The June move originated in a social-velocity spike (+281% in the 3d/14d retail-flow read), not a clinical event. Both cases follow in full.

Bull Case

• 2026-07-16: HELP appeared in two separate gainer screens alongside ATAI and CMPS. Cohort-wide participation is the difference between an isolated single-name pump and a theme with rotational sponsorship; the first is unrepeatable, the second can generate multiple legs.
• 2026-07-09: HC Wainwright maintains Buy, PT cut to $70. Two independent shops (Wainwright $70, Canaccord $42 on 2026-07-01) still publishing Buy after a dilutive raise means the coverage base is intact through the offering.
• 2026-06-24: The $4.85 underwritten deal removed financing risk — the single largest structural overhang on any pre-revenue CNS name — and funds APPROACH through enrollment. The company is no longer trading with a going-concern discount attached.
• 2026-06-29: Fiscal Q4 EPS of $(0.85) against a $(1.11) estimate. A 26-cent narrower loss ahead of a Phase 3 spend ramp indicates the burn assumptions embedded in coverage models are conservative.
• Adjunctive MDD is a large, poorly served indication. Next-gen antidepressant developers have historically re-rated on Phase 2→3 transitions well before any topline, purely on trial-design and enrollment-pace disclosures.

Bear Case

• The June move originated in a social-velocity spike (+281% in the 3d/14d retail-flow read), not a clinical event. Microcaps that reach RSI in the 90s on retail flow revert violently once the attention rotates.
• Issuing 10.3M new shares at $4.85 into that spike is management converting flow into cash. The float is materially larger, and the offering price is a level institutional buyers already agreed was fair — it functions as supply overhead, not a springboard.
• Both covering analysts cut targets in the same fortnight ($70 from a prior level, $42 from a prior level). Direction of revision matters more than absolute level; two cuts in nine days is coverage marking down NPV, even while the rating stays Buy.
• The gap between a $42–$70 target band and a sub-$5 clearing price is the market pricing high probability of binary failure. That spread is not latent upside; it is the discount rate on a multi-year, high-attrition depression trial.
• Nothing dated is scheduled inside 30 days. Absent a catalyst, a second flow impulse decays faster than the first because the marginal buyer is now buying from June's late holders.
• Micro float plus heavy retail ownership produces gap risk in both directions. Stop levels are advisory in a name that can open 20% away from the prior close.

Setup & Price Structure

The chart is a single vertical spike followed by a cooling phase, and no higher-low sequence has formed. The $4.85 secondary print is the reference shelf that matters — it is where the company and an underwriting syndicate transacted size, which makes it the closest thing to a validated fair value the tape has. A constructive sequence looks like this: RSI resetting into the 40s–60s, volume contracting to a fraction of the June peak, then a higher low that holds above $4.85 on a retest. That is the first tradable structure, and it does not exist yet. The 2026-07-16 cohort move is early evidence of re-accelerating interest but arrived without confirming volume expansion in HELP specifically relative to ATAI and CMPS. A daily close back beneath $4.85 puts the entire offering book underwater and confirms the melt-up has fully unwound.

Catalyst Calendar (next 30 days)

• No dated, market-moving catalyst through ~2026-08-18. APPROACH Phase 3 (HLP003, adjunctive MDD) began enrolling 2026-06-24; interim or topline data is quarters-to-years away.
• ~Late August 2026 (est.): next fiscal quarterly update. Watch for enrollment-pace disclosure on APPROACH and cash burn against the ~$50M gross raise — the first fundamental datapoint that can move the name.
• Undated, ongoing: further psychedelic/CNS cohort moves (ATAI, CMPS) are the practical near-term driver. Sector-wide readouts at peers set the multiple for the group.

Elapsed catalysts

• Undated: additional analyst revisions. Both covering shops cut targets between 2026-07-01 and 2026-07-09; a third initiation or a reversal in revision direction would change the coverage signal. (passed 31d ago)

What Would Change Our Mind

• A pullback that holds above $4.85 with RSI resetting under 60 and a clean higher low forming would convert this from a mean-reversion candidate into a legitimate base-and-breakout setup, warranting a small probe.
• Sustained cohort leadership — HELP outperforming ATAI and CMPS across multiple sessions on expanding volume — would indicate the flow is name-specific rather than passive beta to a moving group.
• Any dated interim analysis, DSMB milestone, or accelerated-enrollment disclosure on APPROACH would give the name something to trade toward instead of away from.
• Conversely, a target cut accompanied by a rating downgrade, or a second equity raise at a lower price, would confirm dilution as a recurring feature rather than a one-time clearing event.
• A close below the offering shelf on volume would end the constructive read entirely; there is no support structure beneath it.

Correlation Notes

• Trades as a high-beta member of the psychedelic/next-gen-CNS cohort. ATAI and CMPS are the read-through names; the 2026-07-16 session had all three moving together, which means single-name analysis understates the correlation risk.
• Behaves like a retail-squeeze vehicle, not a clinical compounder: the price responds to social-flow velocity and float mechanics far more than to trial progression. Position sizing should reflect gap risk in a micro-float name.
• Sensitive to biotech risk appetite broadly (XBI). Pre-revenue CNS microcaps are the last to catch a risk-on bid and the first to be sold when rate expectations tighten.
• The $4.85 offering price anchors the name to the small-cap secondary market. A cold financing window for clinical-stage issuers removes the bid that supported the June deal.